Vertex Rallies as Sionna's Cystic Fibrosis Drug Fails Clinical Trials

Vertex Pharmaceuticals' stock has rallied after Sionna Therapeutics' experimental cystic fibrosis drug failed in clinical trials. This outcome highlights the competitive landscape in drug development, where one company's setback can benefit another.